Clinical predictors of mortality in patients with pseudomonas aeruginosa infection.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
12
2022
accepted:
10
02
2023
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Infections caused by Pseudomonas aeruginosa are difficult to treat with a significant cost and burden. In Lebanon, P. aeruginosa is one of the most common organisms in ventilator-associated pneumonia (VAP). P. aeruginosa has developed widespread resistance to multiple antimicrobial agents such as fluoroquinolones and carbapenems. We aimed at identifying risk factors associated for P. aeruginosa infections as well as identifying independent risk factors for developing septic shock and in-hospital mortality. We used a cross-sectional study design where we included patients with documented P. aeruginosa cultures who developed an infection after obtaining written consent. Two multivariable regression models were used to determine independent predictors of septic shock and mortality. During the observed period of 30 months 196 patients were recruited. The most common predisposing factor was antibiotic use for more than 48 hours within 30 days (55%). The prevalence of multi-drug resistant (MDR) P. aeruginosa was 10%. The strongest predictors of mortality were steroid use (aOR = 3.4), respiratory failure (aOR = 7.3), identified respiratory cultures (aOR = 6.0), malignancy (aOR = 9.8), septic shock (aOR = 18.6), and hemodialysis (aOR = 30.9). Understanding resistance patterns and risk factors associated with mortality is crucial to personalize treatment based on risk level and to decrease the emerging threat of antimicrobial resistance.
Sections du résumé
BACKGROUND
Infections caused by Pseudomonas aeruginosa are difficult to treat with a significant cost and burden. In Lebanon, P. aeruginosa is one of the most common organisms in ventilator-associated pneumonia (VAP). P. aeruginosa has developed widespread resistance to multiple antimicrobial agents such as fluoroquinolones and carbapenems. We aimed at identifying risk factors associated for P. aeruginosa infections as well as identifying independent risk factors for developing septic shock and in-hospital mortality.
METHODS
We used a cross-sectional study design where we included patients with documented P. aeruginosa cultures who developed an infection after obtaining written consent. Two multivariable regression models were used to determine independent predictors of septic shock and mortality.
RESULTS
During the observed period of 30 months 196 patients were recruited. The most common predisposing factor was antibiotic use for more than 48 hours within 30 days (55%). The prevalence of multi-drug resistant (MDR) P. aeruginosa was 10%. The strongest predictors of mortality were steroid use (aOR = 3.4), respiratory failure (aOR = 7.3), identified respiratory cultures (aOR = 6.0), malignancy (aOR = 9.8), septic shock (aOR = 18.6), and hemodialysis (aOR = 30.9).
CONCLUSION
Understanding resistance patterns and risk factors associated with mortality is crucial to personalize treatment based on risk level and to decrease the emerging threat of antimicrobial resistance.
Identifiants
pubmed: 37115776
doi: 10.1371/journal.pone.0282276
pii: PONE-D-22-33603
pmc: PMC10146515
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0282276Informations de copyright
Copyright: © 2023 Frem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Glob Antimicrob Resist. 2018 Dec;15:69-73
pubmed: 29906626
Antimicrob Agents Chemother. 2020 Jan 27;64(2):
pubmed: 31767719
Infez Med. 2017 Mar 1;25(1):21-26
pubmed: 28353451
Antibiotics (Basel). 2022 Feb 28;11(3):
pubmed: 35326786
Antimicrob Agents Chemother. 2007 Oct;51(10):3510-5
pubmed: 17646415
BMC Infect Dis. 2014 Mar 24;14:161
pubmed: 24655422
J Glob Antimicrob Resist. 2018 Jun;13:60-64
pubmed: 29154953
J Chemother. 2021 Sep;33(5):294-301
pubmed: 32996875
Antimicrob Agents Chemother. 2019 Jul 25;63(8):
pubmed: 31109983
Int J Mol Sci. 2020 May 12;21(10):
pubmed: 32408613
Rev Esp Quimioter. 2017 Sep;30 Suppl 1:8-12
pubmed: 28882007
Mol Cell Endocrinol. 2011 Mar 15;335(1):2-13
pubmed: 20398732
Clin Pharmacokinet. 2000 Oct;39(4):271-9
pubmed: 11069213
Braz J Infect Dis. 2008 Dec;12(6):509-15
pubmed: 19287840
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
J Infect Public Health. 2019 Jul - Aug;12(4):492-495
pubmed: 30737129
Lancet Infect Dis. 2018 Dec;18(12):e379-e394
pubmed: 30292478
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2019 Oct 1;40(2):25-32
pubmed: 31605588
Int J Antimicrob Agents. 2007 Nov;30(5):458-62
pubmed: 17703923
Int J Mol Sci. 2020 Jul 28;21(15):
pubmed: 32731491
J Glob Infect Dis. 2016 Jan-Mar;8(1):25-31
pubmed: 27013841
Eur J Clin Microbiol Infect Dis. 2019 May;38(5):921-926
pubmed: 30826996
Expert Rev Anti Infect Ther. 2017 Sep;15(9):861-871
pubmed: 28803496
Epidemiol Infect. 2011 Nov;139(11):1740-9
pubmed: 21226988
J Infect Public Health. 2021 Jan;14(1):12-16
pubmed: 33341479
Infect Drug Resist. 2019 Jul 16;12:2125-2133
pubmed: 31406468
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Pharmacotherapy. 2011 Jun;31(6):598-608
pubmed: 21923444
J Antimicrob Chemother. 2019 Jul 1;74(7):1825-1835
pubmed: 30989186
Clin Infect Dis. 2018 Nov 28;67(12):1803-1814
pubmed: 30052813
Infect Drug Resist. 2020 Nov 12;13:4115-4123
pubmed: 33209041
PLoS One. 2013 Nov 08;8(11):e78604
pubmed: 24250801
J Infect. 2006 Jun;52(6):461-3
pubmed: 16621000
J Clin Pharm Ther. 2016 Oct;41(5):532-7
pubmed: 27511808
J Med Microbiol. 2014 Dec;63(Pt 12):1679-1687
pubmed: 25261066
Open Forum Infect Dis. 2021 Oct 06;8(11):ofab485
pubmed: 34805430
J Clin Med. 2020 Feb 14;9(2):
pubmed: 32074947
Saudi Med J. 2010 Dec;31(12):1341-9
pubmed: 21135998
Am J Infect Control. 2014 Sep;42(9):942-56
pubmed: 25179325